EA201892536A1 - Фармацевтические носители, содержащие микрорнк, для применения в лечении фиброзных заболеваний, вызванных гипергликемией - Google Patents

Фармацевтические носители, содержащие микрорнк, для применения в лечении фиброзных заболеваний, вызванных гипергликемией

Info

Publication number
EA201892536A1
EA201892536A1 EA201892536A EA201892536A EA201892536A1 EA 201892536 A1 EA201892536 A1 EA 201892536A1 EA 201892536 A EA201892536 A EA 201892536A EA 201892536 A EA201892536 A EA 201892536A EA 201892536 A1 EA201892536 A1 EA 201892536A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hyperglycemia
treatment
fibrozal
application
diseases caused
Prior art date
Application number
EA201892536A
Other languages
English (en)
Other versions
EA037967B1 (ru
Inventor
Мария Феличе Брицци
Джовани Камусси
Original Assignee
Униците Эф Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Униците Эф Аг filed Critical Униците Эф Аг
Publication of EA201892536A1 publication Critical patent/EA201892536A1/ru
Publication of EA037967B1 publication Critical patent/EA037967B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Botany (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Optics & Photonics (AREA)

Abstract

Настоящее изобретение относится к новому терапевтическому применению фармацевтически приемлемых носителей, содержащих miR222. В частности, настоящее изобретение относится к применению внеклеточных везикул (EV), которые содержат микроРНК miR222, в лечении фиброзного заболевания, вызванного гипергликемией, такого как диабетическая нефропатия и/или почечный фиброз.
EA201892536A 2016-05-06 2017-05-04 ФАРМАЦЕВТИЧЕСКИЕ НОСИТЕЛИ, СОДЕРЖАЩИЕ микроРНК, ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ФИБРОЗНЫХ ЗАБОЛЕВАНИЙ, ВЫЗВАННЫХ ГИПЕРГЛИКЕМИЕЙ EA037967B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16168546 2016-05-06
PCT/EP2017/060612 WO2017191234A1 (en) 2016-05-06 2017-05-04 Pharmaceutical carriers containing mirnas for use in the treatment of fibrotic diseases caused by hyperglycemia

Publications (2)

Publication Number Publication Date
EA201892536A1 true EA201892536A1 (ru) 2019-04-30
EA037967B1 EA037967B1 (ru) 2021-06-16

Family

ID=56008484

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892536A EA037967B1 (ru) 2016-05-06 2017-05-04 ФАРМАЦЕВТИЧЕСКИЕ НОСИТЕЛИ, СОДЕРЖАЩИЕ микроРНК, ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ФИБРОЗНЫХ ЗАБОЛЕВАНИЙ, ВЫЗВАННЫХ ГИПЕРГЛИКЕМИЕЙ

Country Status (13)

Country Link
US (2) US10716813B2 (ru)
EP (2) EP3777897A3 (ru)
JP (1) JP7011605B2 (ru)
KR (1) KR102467150B1 (ru)
CN (1) CN109195637B (ru)
AU (1) AU2017260660B2 (ru)
BR (1) BR112018072797A2 (ru)
CA (1) CA3022921A1 (ru)
DK (1) DK3452100T3 (ru)
EA (1) EA037967B1 (ru)
ES (1) ES2861650T3 (ru)
PL (1) PL3452100T3 (ru)
WO (1) WO2017191234A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI542690B (zh) 2010-05-12 2016-07-21 再生醫學Ｔｘ有限責任公司 生物活性腎細胞
CA3085662A1 (en) * 2017-12-14 2019-06-20 Unicyte Ev Ag Pharmaceutical carriers containing mirnas for use in the treatment of renal cancer
JP2021535135A (ja) * 2018-08-31 2021-12-16 ティモシー エー． ベルトラム， 細胞由来の小胞を含む組成物及びその使用
EP3980526A1 (en) * 2019-06-10 2022-04-13 Unicyte EV AG Extracellular vesicles from human liver stem cells (hlsc-evs) for reducing cellular senescence
CN115463107A (zh) * 2021-06-10 2022-12-13 中山大学 一种工程化囊泡的制备方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001280551B9 (en) * 2000-07-13 2006-01-12 Alteon, Inc. Method for treating fibrotic diseases or other indications ic
WO2006126219A1 (en) 2005-05-26 2006-11-30 Fresenius Medical Care Deutschland G.M.B.H. Liver progenitor cells
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
KR101640381B1 (ko) * 2008-02-22 2016-07-18 에이전시 포 사이언스, 테크놀로지 앤드 리서치 중간엽 줄기세포 입자
US8486909B2 (en) * 2009-06-24 2013-07-16 Board Of Regents Of The University Of Nebraska Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
US8648017B2 (en) * 2009-11-04 2014-02-11 Diamir, Llc Methods of using small RNA from bodily fluids for diagnosis and monitoring of neurodegenerative diseases
TWI542690B (zh) 2010-05-12 2016-07-21 再生醫學Ｔｘ有限責任公司 生物活性腎細胞
AU2011288262A1 (en) * 2010-08-13 2013-04-04 The University Court Of The University Of Glasgow Therapeutic uses of microvesicles and related microRNAs
EP2833893B1 (en) * 2012-04-03 2018-08-29 Reneuron Limited Stem cell microparticles
JP2015529450A (ja) * 2012-07-19 2015-10-08 リニューロン・リミテッドＲｅＮｅｕｒｏｎ Ｌｉｍｉｔｅｄ 幹細胞微粒子
EP3016665B1 (en) * 2013-07-05 2019-09-18 Université Catholique de Louvain Conditioned medium from human adult liver stem cells and its use in the treatment of liver disorders
GB201317887D0 (en) 2013-10-09 2013-11-20 Reneuron Ltd Product
WO2016054094A1 (en) * 2014-09-30 2016-04-07 Research Institute At Nationwide Children's Hospital Compositions and methods for treating hepatic fibrosis
WO2017047800A1 (ja) * 2015-09-16 2017-03-23 国立大学法人東北大学 核酸分子

Also Published As

Publication number Publication date
EP3777897A3 (en) 2021-06-09
WO2017191234A1 (en) 2017-11-09
CA3022921A1 (en) 2017-11-09
PL3452100T3 (pl) 2021-07-19
CN109195637A (zh) 2019-01-11
US20190209619A1 (en) 2019-07-11
US10716813B2 (en) 2020-07-21
JP7011605B2 (ja) 2022-01-26
AU2017260660B2 (en) 2023-12-21
JP2019514964A (ja) 2019-06-06
ES2861650T3 (es) 2021-10-06
CN109195637B (zh) 2022-08-09
EP3452100A1 (en) 2019-03-13
EP3777897A2 (en) 2021-02-17
DK3452100T3 (da) 2021-03-08
KR20190005209A (ko) 2019-01-15
EA037967B1 (ru) 2021-06-16
KR102467150B1 (ko) 2022-11-14
US11110130B2 (en) 2021-09-07
US20200222467A1 (en) 2020-07-16
EP3452100B1 (en) 2020-12-16
AU2017260660A1 (en) 2018-12-20
BR112018072797A2 (pt) 2019-03-12

Similar Documents

Publication Publication Date Title
EA201892536A1 (ru) Фармацевтические носители, содержащие микрорнк, для применения в лечении фиброзных заболеваний, вызванных гипергликемией
PH12017500166A1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
TR201900649T4 (tr) Oküler hastalıkların tedavisi için mrna tedavisi.
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
EA201391106A1 (ru) Новые гетероциклические производные
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201490888A1 (ru) Новые производные пурина и их применение для лечения заболевания
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
BR112015020389A8 (pt) compostos carbazol úteis como inibidores de bromodomínio, seu uso, bem como composição e produto farmacêuticos compreendendo os mesmos
PH12014502449A1 (en) Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
GT201200164A (es) "nuevos compuestos de espiropiperidina"
EA201391315A1 (ru) Гуанидиновое соединение
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
EA201591535A1 (ru) Замещенные производные 3-фенилпропиламина для лечения офтальмологических заболеваний и расстройств
JOP20200231A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
EA201490721A1 (ru) Лекарственное средство для лечения заболеваний передней камеры глаза, включающее ребамипид и агент, удерживающий слезы
EA201500371A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF АГЕНТЫ
EA201590562A1 (ru) Бензамиды
EA201690187A1 (ru) Композиция в форме сухого порошка, содержащая кортикостероид и бета-адренергическое лекарственное средство, для введения ингаляцией
EA201370230A1 (ru) Новые ингибиторы rock
AR092103A1 (es) Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1)
PE20151746A1 (es) Compuestos biciclicos